Common drugs for type 2 diabetes and obesity do not increase breast cancer risk



Commonly used medications for type 2 diabetes and obesity called glucagon like peptide-1 receptor agonists (GLP-1 RAs), are not associated with an increased risk of breast cancer, despite previous studies that suggested a possible link, according to a study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.



Source link

Leave a Reply!

So glad to see you sticking around!

Want to be the first one to receive the new stuff?

Enter your email address below and we'll send you the goodies straight to your inbox.

Thank You For Subscribing!

This means the world to me!

Spamming is not included! Pinky promise.